These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 15848672

  • 21. A single center, open-label, randomized pilot study to evaluate the safety and efficacy of tacrolimus modified release, Advagraf, versus tacrolimus twice daily, Prograf, in stable renal recipients (single).
    Yang SS, Choi JY, Cho WT, Park JB, Kim SJ.
    Transplant Proc; 2015 Apr; 47(3):617-21. PubMed ID: 25891697
    [Abstract] [Full Text] [Related]

  • 22. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf.
    Woillard JB, de Winter BC, Kamar N, Marquet P, Rostaing L, Rousseau A.
    Br J Clin Pharmacol; 2011 Mar; 71(3):391-402. PubMed ID: 21284698
    [Abstract] [Full Text] [Related]

  • 23. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant.
    DuBay DA, Teperman L, Ueda K, Silverman A, Chapman W, Alsina AE, Tyler C, Stevens DR.
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):995-1008. PubMed ID: 30667591
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations.
    Alloway R, Vanhaecke J, Yonan N, White M, Haddad H, Rábago G, Tymchak W, Diaz Molina B, Grimm M, Eiskjaer H, Karpf C, Undre N.
    J Heart Lung Transplant; 2011 Sep; 30(9):1003-10. PubMed ID: 21493098
    [Abstract] [Full Text] [Related]

  • 25. Dose increase needed in most cystic fibrosis lung transplantation patients when changing from twice- to once-daily tacrolimus oral administration.
    Soto GAC, Ruiz-Antorán B, Laporta R, Sancho A, Lázaro MT, Herrera CP, Salcedo I, Cos MA, Torres F, Usetti P, Avendaño-Sola C.
    Eur J Clin Pharmacol; 2015 Jun; 71(6):715-722. PubMed ID: 25953736
    [Abstract] [Full Text] [Related]

  • 26. Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study.
    Lapeyraque AL, Kassir N, Théorêt Y, Krajinovic M, Clermont MJ, Litalien C, Phan V.
    Pediatr Nephrol; 2014 Jun; 29(6):1081-8. PubMed ID: 24435759
    [Abstract] [Full Text] [Related]

  • 27. Renal function, efficacy and safety postconversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study.
    Sańko-Resmer J, Boillot O, Wolf P, Thorburn D.
    Transpl Int; 2012 Mar; 25(3):283-93. PubMed ID: 22239105
    [Abstract] [Full Text] [Related]

  • 28. Three-month experience with tacrolimus once-daily regimen in stable renal allografts.
    Diez Ojea B, Alonso Alvarez M, Aguado Fernández S, Baños Gallardo M, García Melendreras S, Gómez Huertas E.
    Transplant Proc; 2009 Mar; 41(6):2323-5. PubMed ID: 19715908
    [Abstract] [Full Text] [Related]

  • 29. Once-daily, prolonged-release tacrolimus vs twice-daily, immediate-release tacrolimus in de novo living-donor liver transplantation: A Phase 4, randomized, open-label, comparative, single-center study.
    Shin MH, Song GW, Lee SG, Hwang S, Kim KH, Ahn CS, Moon DB, Ha TY, Jung DH, Park GC, Yun YI, Kim WJ, Kang WH, Kim SH, Jiang H, Lee S, Tak EY.
    Clin Transplant; 2018 Sep; 32(9):e13376. PubMed ID: 30098071
    [Abstract] [Full Text] [Related]

  • 30. Conversion from Prograf to Advagraf in adolescents with stable liver transplants: comparative pharmacokinetics and 1-year follow-up.
    Carcas-Sansuán AJ, Hierro L, Almeida-Paulo GN, Frauca E, Tong HY, Díaz C, Piñana E, Frías-Iniesta J, Jara P.
    Liver Transpl; 2013 Oct; 19(10):1151-8. PubMed ID: 23894093
    [Abstract] [Full Text] [Related]

  • 31. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels.
    Crespo M, Mir M, Marin M, Hurtado S, Estadella C, Gurí X, Rap O, Moral R, Puig JM, Lloveras J.
    Transplant Proc; 2009 Oct; 41(6):2115-7. PubMed ID: 19715848
    [Abstract] [Full Text] [Related]

  • 32. Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism.
    Uchida J, Kuwabara N, Machida Y, Iwai T, Naganuma T, Kumada N, Nakatani T.
    Transplant Proc; 2012 Jan; 44(1):128-33. PubMed ID: 22310596
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients.
    Song GW, Lee SG, Hwang S, Kim KH, Kim WJ, Sin MH, Yoon YI, Tak EY.
    Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646
    [Abstract] [Full Text] [Related]

  • 35. The association between trough blood concentration and systemic exposure of tacrolimus: Comparison between once-daily (Advagraf®) and twice-daily (Prograf®) formulation in de novo kidney transplant recipients.
    Sukkha S, Chindavijak B, Nosoongnoen W, Phakdeekitchareon B, Kitiyakara C, Sumethkul V.
    Drug Metab Pharmacokinet; 2020 Feb; 35(1):139-144. PubMed ID: 31727575
    [Abstract] [Full Text] [Related]

  • 36. Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure.
    Yau WP, Loh CW, Vathsala A.
    Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):481-492. PubMed ID: 30471066
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Effect of Breakfast on the Exposure of the Once-Daily Tacrolimus Formulation in Stable Kidney Transplant Recipients.
    Stifft F, Undre N, van Hooff JP, Christiaans MH.
    Ther Drug Monit; 2016 Aug; 38(4):456-62. PubMed ID: 27128604
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Pilot Study Comparing the Efficacy, Safety, Convertibility, and Tacrolimus Trough Levels of Twice-Daily Tacrolimus (Prograf) to Once-Daily Tacrolimus (Advagraf) Among Standard-Risk Kidney Transplant Patients at the National Kidney and Transplant Institute.
    Danguilan RA, Lamban A, Pamugas GEP.
    Transplant Proc; 2019 Oct; 51(8):2615-2619. PubMed ID: 31563241
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.